Pirenzia is developing new, revolutionary vaccines using DNA shuffling technology to first address the agricultural swine flu market, and longer term, human flu vaccines to keep communities safer.
You deserve the best protection
Our Goal is Vaccines that will Outperform Anything On The Market
Pirenzia has spent the last seven years working on proprietary vaccine development approaches that hold the potential to dramatically improve flu immunization for people as well as for the health and livelihood of agricultural businesses across the world. Pirenzia's commitment to health has lead us to research we believe will result in new, faster-to-adapt and more universal vaccines.
Ready to learn more?
Contact Us TodayProducts & Production
Reliable, Tested, and Steady Progress
Vaccine technology continues to march forward and Pirenzia is part of that push. Our lead products in development are targeted to be agricultural vaccinations that are all-encompassing for swine flu variations. Our development is state-of-the-art and our delivery methods are revolutionary. Longer term, we will work toward a universal flu vaccine for human flu variants.
Agricultural Vaccinations
Prevent Infection and Halt Transmission
Pirenzia’s goal is to produce vaccines which will inoculate swine against multiple strains of flu at once and prevent animal-to-human disease transmission.
Many flus, including the swine flu, mutate inside of livestock and move to new human hosts. We are working on vaccine development procedures targeted at preventing the spread of another fatal outbreak of H1N1, H3N2, or H5N1 variants.
In addition during the next several years, Pirenzia aims to vaccinate farm-grown birds to prevent the transmission of avian flu.
Human Flu Vaccinations
Our Goal is to Make Staying Healthy Easier
Pirenzia will begin the certification process for human trials and treatment as soon as possible.
Pirenzia is on track to developing a vaccine that is more effective to administer, gentler on the immune system, and faster, quicker, & easier to produce than competing vaccines. With our sole rights to the patented chimeric HA protein, known as HA-113, that induces broad immunity within the H1 HA flu subtype, we've been able to make significant progress in vaccine development that we believe will have significant impact.
Reach out for more information.
Delivery Methods
Multiple Potential Partnerships With Several Delivery Method Developers.
Pirenzia is considering a multi-faceted approach to vaccination.
We're currently in talks with one potential partner to use their nanoparticle delivery system in the application of Pirenzia's vaccinations. We're also working on a partnership with a nasal spray applicator—that's all we can say for now.
Using multiple delivery methods will allow us to make our vaccinations more accessible and more efficient to administer.
Looking Toward the Future
Ongoing Development for Different Diseases
After Pirenzia creates vaccines for critical flu variants, we've set our sights on developing vaccines for less common—but more deadly—illnesses.
Our future vaccine development will begin with developing a vaccine for Swine Fever, a highly contagious and deadly viral disease in domestic and wild pigs. Swine Fever is responsible for serious economic losses to farmers across the world and we believe that it is important that more vaccination options become available.
We Can Help
Contact Us TodayReady to learn more?
Contact Us TodayHow Can We Help?
Contact Us TodayContact Us
Please tell us who sent you to Pirenzia.
All fields are required.